Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
TransCardiac Therapeutics
AddedFeb 18, 2024
UpdatedJun 18, 2026
TransCardiac Therapeutics

TransCardiac Therapeutics

Atlanta-based TransCardiac Therapeutics develops innovative, minimally invasive cardiac therapies without major surgery.

HQ
Atlanta, GA, US
Founded
2003
Overview
Compare
Fundraising
Employees

TransCardiac Therapeutics, founded in 2003 by Dr. Omar Lattouf of Emory University, is dedicated to developing minimally invasive cardiac therapies. The company's technologies aim to access specific sites on the heart without large surgical incisions, enhancing patient outcomes and recovery times.

TransCardiac Therapeutics has made significant strides in cardiac care, contributing to the advancement of less invasive treatment options. Their innovative approach has positioned them as a key player in the cardiac therapy market, impacting both patient care and medical practices.

TransCardiac Therapeutics - Quick Facts

When was TransCardiac Therapeutics founded?

TransCardiac Therapeutics was founded in 2003.

Where is TransCardiac Therapeutics' headquarters located?

TransCardiac Therapeutics' headquarters is located in Atlanta, GA, US.

When was TransCardiac Therapeutics' last funding round?

TransCardiac Therapeutics' most recent funding round was for $200k (USD) in July 2009.

How much has TransCardiac Therapeutics raised to-date?

As of Jul 30, 2009, TransCardiac Therapeutics has raised a total of $200k (USD).

How many employees does TransCardiac Therapeutics have?

TransCardiac Therapeutics has 30 employees as of Feb 5, 2024.

TransCardiac Therapeutics - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Medical Devices
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cardiac Therapies
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 17 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 330000Manufacturing
  • 325000Chemical Manufacturing
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 325410Pharmaceutical and Medicine Manufacturing
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 5000Wholesale Trade-durable Goods
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 5040Professional And Commercial Equipment And Supplies
  • 8730Research, Development, And Testing Services
  • 5047Medical, Dental, And Hospital Equipment And Supplies
  • 8731Commercial Physical and Biological Research